HK1024424A1 - Methods of therapeutic administration of anti-cd40l compounds - Google Patents

Methods of therapeutic administration of anti-cd40l compounds

Info

Publication number
HK1024424A1
HK1024424A1 HK00103914A HK00103914A HK1024424A1 HK 1024424 A1 HK1024424 A1 HK 1024424A1 HK 00103914 A HK00103914 A HK 00103914A HK 00103914 A HK00103914 A HK 00103914A HK 1024424 A1 HK1024424 A1 HK 1024424A1
Authority
HK
Hong Kong
Prior art keywords
methods
therapeutic administration
cd40l compounds
cd40l
compounds
Prior art date
Application number
HK00103914A
Other languages
English (en)
Inventor
Susan L Kalled
David W Thomas
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of HK1024424A1 publication Critical patent/HK1024424A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK00103914A 1997-01-10 2000-06-28 Methods of therapeutic administration of anti-cd40l compounds HK1024424A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3467297P 1997-01-10 1997-01-10
US4015497P 1997-03-07 1997-03-07
PCT/US1998/000573 WO1998030241A1 (fr) 1997-01-10 1998-01-09 Procedes d'administration therapeutique de composes anti-cd40l

Publications (1)

Publication Number Publication Date
HK1024424A1 true HK1024424A1 (en) 2000-10-13

Family

ID=26711241

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00103914A HK1024424A1 (en) 1997-01-10 2000-06-28 Methods of therapeutic administration of anti-cd40l compounds

Country Status (21)

Country Link
US (2) US20020071840A1 (fr)
EP (1) EP0966302B1 (fr)
JP (1) JP2001508450A (fr)
KR (2) KR100632846B1 (fr)
CN (1) CN1248921A (fr)
AT (1) ATE356634T1 (fr)
AU (1) AU721697B2 (fr)
BR (1) BR9807471A (fr)
CA (1) CA2277223A1 (fr)
CZ (1) CZ244399A3 (fr)
DE (1) DE69837322T2 (fr)
EA (1) EA001426B1 (fr)
EE (1) EE9900275A (fr)
HK (1) HK1024424A1 (fr)
IL (1) IL130785A0 (fr)
IS (1) IS5101A (fr)
NO (1) NO993275L (fr)
NZ (1) NZ337073A (fr)
PL (1) PL193966B1 (fr)
TR (1) TR199902192T2 (fr)
WO (1) WO1998030241A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
NZ500974A (en) * 1997-05-17 2001-06-29 Biogen Inc Use of a CD40:CD154 binding interruptor to prevent counter adaptive immune responses in graft rejection
JP2002504910A (ja) * 1997-06-20 2002-02-12 バイオジェン，インコーポレイテッド 治療用タンパク質阻害因子症候群のためのｃｄ１５４遮断治療
CA2343916A1 (fr) * 1998-09-21 2000-03-30 Genetics Institute, Inc. Methodes de modulation restrictive de la reponse immunitaire aux proteines therapeutiques
WO2000072882A1 (fr) * 1999-06-01 2000-12-07 Eisai Co., Ltd. Agents prophylactiques du purpura thrombocytopenique idiopathique
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
EP1262194A4 (fr) * 2000-03-06 2003-05-07 Eisai Co Ltd Agents therapeutiques et prophylactiques diriges contre le syndrome des antiphospholipides
WO2001079555A2 (fr) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles des membres de la famille jak/stat dans l'induction de la tolerance
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
BR0111158A (pt) 2000-05-12 2004-04-06 Genzyme Corp Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente
JP3785508B2 (ja) * 2002-04-15 2006-06-14 学校法人慶應義塾 遺伝子治療における免疫応答を解析できる実験モデルマウス
EP1562571B1 (fr) * 2002-11-21 2011-08-17 Genzyme Corporation Combinaison d'un derive de diamide et d'agents immunosuppresseurs pour inhiber le rejet de greffe
ES2650267T3 (es) 2008-12-05 2018-01-17 Als Therapy Development Institute Método para el tratamiento de enfermedades neurodegenerativas

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
DE69418349T2 (de) * 1993-09-02 1999-09-09 Trustees Of Dartmouth College Verfahren zur verlaengerter unterdrueckung der humoralen immunitaet
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
EP0721469B1 (fr) * 1993-09-02 2000-01-05 Trustees of Dartmouth College Anticorps anti-gp39 et leurs utilisations
DE69433820T2 (de) * 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
DK0892643T4 (da) * 1996-03-20 2009-12-14 Bristol Myers Squibb Co Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved

Also Published As

Publication number Publication date
BR9807471A (pt) 2000-03-21
NO993275D0 (no) 1999-07-01
JP2001508450A (ja) 2001-06-26
DE69837322T2 (de) 2007-11-22
IL130785A0 (en) 2001-01-28
AU721697B2 (en) 2000-07-13
NZ337073A (en) 2001-01-26
EE9900275A (et) 2000-02-15
US20020071840A1 (en) 2002-06-13
KR20000070035A (ko) 2000-11-25
EP0966302B1 (fr) 2007-03-14
AU5735398A (en) 1998-08-03
KR20050088494A (ko) 2005-09-06
IS5101A (is) 1999-06-30
EA199900633A1 (ru) 2000-02-28
DE69837322D1 (de) 2007-04-26
PL193966B1 (pl) 2007-04-30
PL334500A1 (en) 2000-02-28
CA2277223A1 (fr) 1998-07-16
KR100632846B1 (ko) 2006-10-16
US20050158314A1 (en) 2005-07-21
CN1248921A (zh) 2000-03-29
ATE356634T1 (de) 2007-04-15
TR199902192T2 (xx) 1999-12-21
WO1998030241A1 (fr) 1998-07-16
CZ244399A3 (cs) 1999-10-13
EA001426B1 (ru) 2001-02-26
EP0966302A1 (fr) 1999-12-29
NO993275L (no) 1999-09-09

Similar Documents

Publication Publication Date Title
HK1024424A1 (en) Methods of therapeutic administration of anti-cd40l compounds
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
IL151164A0 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
IL207358A (en) Combined treatments for B-cell lymphomas that include the provision of anti-cd20 antibody
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
IL192287A0 (en) Pharmaceutical compositions and methods for use
GB9727131D0 (en) Therapeutic agents
HK1043315A1 (en) Triazineone compounds for treating diseases due tosarcosystis, neospora and toxoplasma.
HUP0001263A2 (hu) Eljárások anti-CD4OL vegyületek gyógyászati alkalmazásaira
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
DK1140103T3 (da) Ponazuril til behandling af neurologiske og abortfremkaldende sygdomme forårsaget af Coccidia
EP1056458A4 (fr) Procede de traitement de la douleur, notamment de la douleur chronique et specifique aux femmes
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
ATE248607T1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
EA199800941A1 (ru) Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110109